Detalhe da pesquisa
1.
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
Lancet Oncol
; 23(5): 659-670, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427471